Skip to main content
. 2021 Nov 6;38:100887. doi: 10.1016/j.gore.2021.100887

Table 2.

Chemotherapeutic and surgical outcomes for included studies.

NACT PDS Response to NACT NACT patients receiving IDS Extent of Debulking Surgery
Additional Findings
n n n (%) n (%) NACT+IDS, n(%) PDS, n(%)
Bogani et al., 2019 15 15 NR 15 (100) 14 (93) complete
1 (7) optimal
13 (87) complete
2 (13) optimal
p = 0.96 for debulking outcomes
• NACT arm with significantly shorter hospital stays (4 vs. 6d, p = 0.011)
• NACT arm trend towards shorter op. time (127 vs. 177.6, p = 0.072) and trend towards lower transfusion rates (6.6% vs. 33.3%, p = 0.067)
de Lange et al., 2019 102 4 (4) CR
73 (72) PR
9 (9) SD
11 (11) PD
2 (2) died during treatment
3 (3) no imaging available
80 (78) 48 (60) complete
23 (29) optimal
9 (11) suboptimal
Eto et al., 2013 125 279 40 (68) CR/PR
9 (15) SD
7 (12) PD
3 (5) not evaluable
•responses to NACT reported only for patients who received IDS
59 (47) 19 (32) complete
15 (25) optimal
25 (43) suboptimal
61 (22) complete
65 (23) optimal
153 (55) suboptimal
p = 0.087 for optimal cytoreduction
Holman et al., 2017 27 233 8 (30) CR
9 (33) PR/SD
10 (37) PD
17 (63) NR NR
Khouri et al., 2019 39 22 (56) PR
1 (3) SD
16 (41) PD
16 (41) 13 (81) complete/optimal
3 (19) suboptimal
Rajkumar et al., 2019 17 28 NR 17 (100) NR NR
Tobias et al., 2020 952 3938 NR 555 (58) NR NR
Vandenput et al., 2009 30 2 (7) CR
20 (67) PR
6 (20) SD
2 (7) PD
24 (80) 22 (92) complete
2 (8) optimal
Wilkinson-Ryan et al., 2015 10 34 Average decline in CA 125 post-NACT = 91 ± 11% 10 (100) 7 (70) complete
3 (30) optimal
11 (32) complete
17 (50) optimal
6 (18) suboptimal
p = 0.10 for debulking outcomes
•NACT arm with significantly shorter mean operative time (136.9 vs. 202.6 min., p = 0.025) and length of hospital stay (3 vs. 5 d., p = 0.0021)
•NACT arm with trend towards less blood loss (410ml vs. 781.8ml, p = 0.063)

CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NR = not reported.